Cargando…

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy

Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatterjee, Samit, Lesniak, Wojciech G., Nimmagadda, Sridhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676497/ https://www.ncbi.nlm.nih.gov/pubmed/28707500 http://dx.doi.org/10.1177/1536012117718459

Ejemplares similares

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
por: Chatterjee, Samit, et al.
Publicado: (2016)

Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
por: Nimmagadda, Sridhar
Publicado: (2020)

Development of [(18)F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide
por: Lesniak, Wojciech G., et al.
Publicado: (2019)

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018)

Efficacy and safety of immune checkpoint blockade for brain metastases
por: Harary, Maya, et al.
Publicado: (2019)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020)

A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts
por: Azad, Babak Behnam, et al.
Publicado: (2016)

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
por: Minami, Yasunori, et al.
Publicado: (2022)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
por: Ravi, Rajani, et al.
Publicado: (2018)

Peptide-Based (68)Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer
por: De Silva, Ravindra A., et al.
Publicado: (2018)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker
por: Oualla, Karima, et al.
Publicado: (2021)

PD-1 and its ligands are important immune checkpoints in cancer
por: Dong, Yinan, et al.
Publicado: (2016)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice
por: Garcia, Myrna G., et al.
Publicado: (2022)

Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis
por: Duchnowska, Renata, et al.
Publicado: (2016)

The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors
por: Romano, Emanuela, et al.
Publicado: (2015)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
por: Harter, Patrick N., et al.
Publicado: (2015)

Heterogeneous PD-L1 expression in metastases impacts immunotherapy response
por: Hu, Xiaoqian, et al.
Publicado: (2023)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
por: Hogg, Simon J., et al.
Publicado: (2017)

Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands
por: Kamali, Ali N., et al.
Publicado: (2023)

FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
por: Symeonides, Stefan N., et al.
Publicado: (2017)

Checkpoint immunotherapy for NK/T cell lymphoma—Time for a showdown?
por: Chan, Jason Yongsheng, et al.
Publicado: (2021)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
por: Li, Yongshu, et al.
Publicado: (2016)

Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review
por: Peña-Cardelles, Juan Francisco, et al.
Publicado: (2021)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy
por: Wang, Yuqing, et al.
Publicado: (2022)

Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
por: Zhao, Guo, et al.
Publicado: (2023)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80
por: Kennedy, Alan, et al.
Publicado: (2023)

Non-invasive PD-L1 quantification using [(18)F]DK222-PET imaging in cancer immunotherapy
por: Mishra, Akhilesh, et al.
Publicado: (2023)

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
por: Alsaab, Hashem O., et al.
Publicado: (2017)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dccq52s8tcco9t9687at2mlv09